Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) ...

The agreement grants the Japanese pharma the worldwide license to initially use Sangamo's proprietary neurotropic ...

Sangamo Therapeutics, Inc. has groundbreaking treatments for neuropathic pain and Hemophilia A. Click for my updated look at ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Thursday said it has signed an agreement with Sangamo Therapeutics, Inc. (SGMO) to leverage Sangamo's proprietary neurotropic adeno-associated virus (AAV) ...

Astellas signs license agreement with Sangamo Therapeutics to deliver genomic medicines for neurological diseases: Tokyo and Richmond, Calif Saturday, December 21, 2024, 10:00 Hrs ...

Sangamo Therapeutics, Inc. , a genomic medicine company and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced they have entered into a license agreement ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...